According to the most recent American Addiction Center record, almost 80 percent of people have suffered from substance use disorder in the US. The most affected populations are young adults between age 18 to 25 and older adults from age 57 to 85. Among the affected population, males make up a larger portion than females.
Figures have also shown that prescription drugs are now the second most commonly abused substances in the US. An approximate 100 people die every day in the U.S. from drug overdoses, with opioid pharmaceuticals being the leading cause of fatal overdose, surpassing both heroin and cocaine.
Nevada ranks in the top ten states for drug and alcohol abuse; ranking third out of the top five in the percentage of resident’s dependent on illegal substances. The state is also second in the country for non-medical use of oxycodone. Recent figures have shown that per capita sales of oxycodone have increased 366% in the last 10 years.
Some victims of Nevada’s prescription drug abuse epidemic are addicted to multiple drugs and in 2015, Nevada providers wrote 83.0 opioid prescriptions per 100 persons (2.4 million prescriptions). In the same year, the average U.S. rate was 70 opioid prescriptions per 100 persons.
Offering the most comprehensive drugs of abuse screen on the market, Randox Toxicology’s extensive drugs of abuse test menu covers a broad range of classical, prescription and synthetic drugs and drug metabolites including oxycodone.
Utilising our patented Biochip Array Technology, the Evidence range of immunoanalysers have been developed with boundary pushing engineering and are designed to make financial, labour and time savings for the end user. Whilst delivering cutting-edge multiplex testing capabilities, our Biochip Array Technology provides rapid and accurate drug detection from a single sample.
-132 tests per hour
-Ideal for workplace, custodial or laboratory drug testing
-Semi-automated, bench top analyser
-2376 tests in 70 minutes
-Ideal for small to medium sized laboratories